MELODEM statement on aducanumab

In response to the recent controversial FDA accelerated approval of aducanumab to treat Alzheimer’s Disease, MELODEM leadership has created a statement addressing the need for treatment rollout that is structured to deliver clear and timely evidence on efficacy. To read the statement, please view the document below.


View all posts